Показано 0 из 0
Дата |
---|
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
18.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.87
|
0.92
|
0.95
|
0.8694
|
1.00
|
0.88
|
|
|
263 834.46
|
1 683.00
|
0.93
|
1.04
|
1.04
|
0.9411
|
1.06
|
0.9455
|
|
|
425 984.82
|
2 062.00
|
1.00
|
1.10
|
1.20
|
1.00
|
1.20
|
1.00
|
|
|
2 488 748.24
|
1 894.00
|
1.12
|
1.21
|
1.08
|
1.06
|
1.24
|
1.20
|
|
|
568 193.73
|
2 624.00
|
0.93
|
1.52
|
1.05
|
0.918
|
1.08
|
1.06
|
|
|
296 442.13
|
1 921.00
|
1.05
|
1.52
|
1.10
|
1.05
|
1.13
|
1.06
|
|
|
119 787.04
|
1 874.00
|
1.08
|
1.15
|
1.14
|
1.10
|
1.16
|
1.11
|
|
|
178 498.61
|
1 291.00
|
1.09
|
1.15
|
1.11
|
1.09
|
1.15
|
1.10
|
|
|
556 188.83
|
1 298.00
|
1.08
|
1.32
|
1.12
|
1.09
|
1.14
|
1.11
|
|
|
420 811.56
|
1 530.00
|
1.08
|
1.30
|
1.19
|
1.12
|
1.19
|
1.12
|
|
|
780 488.81
|
1 614.00
|
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development.